132 related articles for article (PubMed ID: 11880241)
1. Reduction in hepatic non-esterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats.
Funatsu T; Goto M; Kakuta H; Suzuki M; Ida M; Nishijima S; Tanaka H; Yasuda S; Miyata K
Biochim Biophys Acta; 2002 Feb; 1580(2-3):161-70. PubMed ID: 11880241
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an MTP inhibitor.
Funatsu T; Kakuta H; Takasu T; Miyata K
Eur J Pharmacol; 2002 Nov; 455(2-3):161-7. PubMed ID: 12445582
[TBL] [Abstract][Full Text] [Related]
3. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
[TBL] [Abstract][Full Text] [Related]
4. Experimental model of postprandial hypertriglyceridemia in sucrose-fed rats and the effectiveness of atorvastatin in the model.
Funatsu T; Kakuta H; Takasu T; Noguchi M; Suzuki M; Miyata K
Metabolism; 2003 May; 52(5):609-15. PubMed ID: 12759892
[TBL] [Abstract][Full Text] [Related]
5. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
Krause BR; Newton RS
Atherosclerosis; 1995 Oct; 117(2):237-44. PubMed ID: 8801869
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats.
Roglans N; Sanguino E; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
J Pharmacol Exp Ther; 2002 Jul; 302(1):232-9. PubMed ID: 12065722
[TBL] [Abstract][Full Text] [Related]
7. Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity.
Mangaloglu L; Cheung RC; Van Iderstine SC; Taghibiglou C; Pontrelli L; Adeli K
Metabolism; 2002 Apr; 51(4):409-18. PubMed ID: 11912545
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
[TBL] [Abstract][Full Text] [Related]
9. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.
Oscarsson J; Hurt-Camejo E
Lipids Health Dis; 2017 Aug; 16(1):149. PubMed ID: 28797250
[TBL] [Abstract][Full Text] [Related]
10. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
Roglans N; Verd JC; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
Lipids; 2002 May; 37(5):445-54. PubMed ID: 12056585
[TBL] [Abstract][Full Text] [Related]
11. Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells.
Funatsu T; Suzuki K; Goto M; Arai Y; Kakuta H; Tanaka H; Yasuda S; Ida M; Nishijima S; Miyata K
Atherosclerosis; 2001 Jul; 157(1):107-15. PubMed ID: 11427209
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins.
Ishigami M; Yamashita S; Sakai N; Hirano K; Hiraoka H; Nakamura T; Matsuzawa Y
Atherosclerosis; 2003 Jun; 168(2):359-66. PubMed ID: 12801620
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
[TBL] [Abstract][Full Text] [Related]
14. Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients.
Parhofer KG; Laubach E; Barrett PH
J Lipid Res; 2003 Jun; 44(6):1192-8. PubMed ID: 12671031
[TBL] [Abstract][Full Text] [Related]
15. Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment.
Vilà L; Rebollo A; Ađalsteisson GS; Alegret M; Merlos M; Roglans N; Laguna JC
Toxicol Appl Pharmacol; 2011 Feb; 251(1):32-40. PubMed ID: 21122807
[TBL] [Abstract][Full Text] [Related]
16. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
Chan DC; Watts GF; Barrett PH; Beilin LJ; Redgrave TG; Mori TA
Diabetes; 2002 Aug; 51(8):2377-86. PubMed ID: 12145148
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.
Dallinga-Thie GM; Berk-Planken II; Bootsma AH; Jansen H;
Diabetes Care; 2004 Jun; 27(6):1358-64. PubMed ID: 15161788
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4.
Sanguino E; Roglans N; Alegret M; Sánchez RM; Vázquez-Carrera M; Laguna JC
Br J Pharmacol; 2005 Aug; 145(7):853-61. PubMed ID: 15912134
[TBL] [Abstract][Full Text] [Related]
19. Plasma lipoproteins and regulation of hepatic metabolism of fatty acids in altered thyroid states.
Heimberg M; Olubadewo JO; Wilcox HG
Endocr Rev; 1985; 6(4):590-607. PubMed ID: 3908084
[TBL] [Abstract][Full Text] [Related]
20. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
Diabetes Atorvastin Lipid Intervention (DALI) Study Group
Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
